Position in MDGL
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$881,671
-$945,238 QoQ
Shares Held
1,642
-53.0% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#203
of 411 holders
Holding Since
Mar 2024
6 quarters on record
Voting authority
Sole 98%
Shared 0%
None 2%
Common Shares in MDGL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Calamos Advisors LLC holds $119,502,354 across 21 Biotechnology names. MDGL ranks #18 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
75,388 | $37,447,481 | |
| 2 | RPRX |
Royalty Pharma plc
|
573,521 | $32,157,322 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
11,578 | $7,219,346 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
22,435 | $7,091,478 | |
| 5 | TVTX |
Travere Therapeutics, Inc.
|
121,755 | $6,916,901 | |
| 6 | CYTK |
Cytokinetics Inc
|
51,443 | $4,382,428 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
19,711 | $3,691,476 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
|
14,699 | $3,597,874 |
All Filings in MDGL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $881,671 | 1,642 | Shares | Other | 2026-07-31 | |
| 2026-03-31 | $1,826,909 | 3,490 | Shares | Other | 2026-05-04 | |
| 2025-12-31 | $3,823,643 | 6,566 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $2,057,089 | 4,485 | Shares | Sole | 2025-10-20 | |
| 2024-06-30 | $1,152,017 | 4,112 | Shares | Sole | 2024-07-25 | |
| 2024-03-31 | $964,814 | 3,613 | Shares | Sole | 2024-05-08 | |
| No filing history on record for this holder in this stock. | ||||||